Elanco has a long, positive track record when it comes to evaluating products and bringing them to market successfully. This experience will guide our product development efforts in the companion animal health field.

Watch this website for new products that will enable veterinarians to help pets live longer, healthier, higher-quality lives.

Comfortis^® is the first FDA-approved, chewable, beef-flavored tablet that kills fleas and prevents flea infestations on dogs for a full month.

To learn more about Comfortis^® (spinosad), click here.

Reconcile^® is a once daily, chewable, beef flavored tablet that treats separation anxiety in conjunction with a behavior modification plan.

To learn more about Reconcile^® (fluoxetine hydrochloride), click here.

Comfortis^® Important Safety Information

• The most common adverse reaction reported is vomiting.
• Other adverse reactions reported in decreasing order of frequency are: depression/lethargy, decreased appetite, incoordination, diarrhea, itching, trembling, excessive salivation and seizures.
• Following concomitant extra label use of ivermectin with Comfortis^®, some dogs have experienced the following clinical signs: trembling/twitching, salivation /drooling, seizures, incoordination, excessive dilation of pupils, blindness and disorientation.
• Post approval experience continues to support the safety of Comfortis^® when used concurrently with heartworm preventatives according to label directions.
• For full product label, including complete safety information, click here.

Reconcile^® Important Safety Information

• The most common adverse reactions recorded during clinical trials with Reconcile^® were calm or lethargy, reduced appetite, vomiting, shaking, diarrhea, restlessness, excessive vocalization, aggression, and, in infrequent cases, seizures.
• Reconcile^® chewable tablets are contraindicated for dogs with epilepsy or a history of seizures; with drugs that lower the seizure threshold; with a monoamine oxidase inhibitor (MAOI) or within a minimum of 14 days of discontinuing therapy with an MAOI; in dogs with a known hypersensitivity to fluoxetine HCl or other SSRIs.
• A six week washout interval should be observed following discontinuation of therapy with Reconcile^® chewable tablets prior to the administration of any drug that may adversely interact with fluoxetine or norfluoxetine.
• For full product label, including complete safety information, click here.